{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T08:48:06Z","timestamp":1792140486954,"version":"4.4.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Spinal muscular atrophy (SMA) is a neurodegenerative disease caused by mutations in the survival motor neuron 1 (\n                      <jats:italic>SMN1<\/jats:italic>\n                      ) gene. In clinical studies, gene replacement therapy with onasemnogene abeparvovec (formerly AVXS-101, Zolgensma\n                      <jats:sup>\u00ae<\/jats:sup>\n                      , Novartis) was efficacious in improving motor functioning in children with SMA. However, its effects on cognitive and language skills are largely unknown.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This longitudinal observational study evaluated changes in motor and neurocognitive functioning over a 1-year period after administration of onasemnogene abeparvovec in 12 symptomatic SMA type 1 patients with two copies of\n                      <jats:italic>SMN2<\/jats:italic>\n                      aged 1.7\u201352.6 months at administration. Motor functioning was measured using the Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND) while neurocognitive assessment was measured using Griffiths III. Motor milestones and language ability were also assessed at each timepoint.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results and discussion<\/jats:title>\n                    <jats:p>\n                      Statistically significant increases in median CHOP-INTEND scores from baseline were observed at 1, 3, 6, and 12 months after onasemnogene abeparvovec administration (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2264 0.005). Most (91.7%) patients were able to roll over or sit independently for &amp;gt;1 min at 12 months. Significant increases in the Griffiths III\n                      <jats:italic>Foundations of Learning, Language and Communication, Eye and Hand Coordination<\/jats:italic>\n                      , and\n                      <jats:italic>Personal-Social-Emotional<\/jats:italic>\n                      subscale scores were observed at 12-months, but not in the\n                      <jats:italic>Gross Motor<\/jats:italic>\n                      subscale. Speech and language abilities progressed in most patients. Overall, most patients showed some improvement in cognitive and communication performance after treatment with onasemnogene abeparvovec in addition to significant improvement in motor functioning and motor milestones. Evaluation of neurocognitive function should be considered when assessing the global functioning of patients with SMA.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2024.1326528","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:50:46Z","timestamp":1708476646000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Motor and neurocognitive profiles of children with symptomatic spinal muscular atrophy type 1 with two copies of SMN2 before and after treatment: a longitudinal observational study"],"prefix":"10.3389","volume":"15","author":[{"given":"Ilaria","family":"Bitetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"Manna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Stella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Varone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","article-title":"Spinal muscular atrophy","volume":"371","author":"Lunn","year":"2008","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/ajmg.10425","article-title":"Genetic risk assessment in carrier testing for spinal muscular atrophy","volume":"110","author":"Ogino","year":"2002","journal-title":"Am J Med Genet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J Rare Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0960-8966(91)90052-T","article-title":"International sma collaboration","volume":"1","author":"Munsat","year":"1991","journal-title":"Neuromuscul Disord."},{"key":"B5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell."},{"key":"B6","doi-asserted-by":"publisher","first-page":"7896","DOI":"10.3390\/ijms22157896","article-title":"Genomic variability in the survival motor neuron genes (SMN1 and SMN2): implications for spinal muscular atrophy phenotype and therapeutics development","volume":"22","author":"Butchbach","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00439-019-01983-0","article-title":"Complete sequencing of the SMN2 gene in sma patients detects smn gene deletion junctions and variants in SMN2 that modify the sma phenotype","volume":"138","author":"Ruhno","year":"2019","journal-title":"Hum Genet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s13023-022-02455-x","article-title":"Natural history of type 1 spinal muscular atrophy: a retrospective, global, multicenter study","volume":"17","author":"Cances","year":"2022","journal-title":"Orphanet J Rare Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural history of infantile-onset spinal muscular atrophy","volume":"82","author":"Kolb","year":"2017","journal-title":"Ann Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13023-022-02227-7","article-title":"Natural history of respiratory muscle strength in spinal muscular atrophy: a prospective national cohort study","volume":"17","author":"Veldhoen","year":"2022","journal-title":"Orphanet J Rare Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.7499\/j.issn.1008-8830.2106025","article-title":"Natural history of spinal muscular atrophy in children: an analysis of 117 cases","volume":"23","author":"Yang","year":"2021","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi."},{"key":"B12","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/dmcn.14798","article-title":"Brain, cognition, and language development in spinal muscular atrophy type 1: a scoping review","volume":"63","author":"Masson","year":"2021","journal-title":"Dev Med Child Neurol."},{"key":"B13","unstructured":"Zolgensma (Onasemnogene Abeparvovec)."},{"key":"B14","unstructured":"Zolgensma"},{"key":"B15","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (Str1ve): an open-label, single-arm, multicentre, phase 3 Trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-year extension results of the phase 1 start trial of onasemnogene abeparvovec in spinal muscular atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1136\/jnnp-2022-ABN.2","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (str1ve-eu): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s41434-022-00341-6","article-title":"Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study","volume":"30","author":"Bitetti","year":"2023","journal-title":"Gene Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2352-4642(21)00287-X","article-title":"Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study","volume":"6","author":"Wei\u00df","year":"2022","journal-title":"Lancet Child Adoles Health."},{"key":"B22","doi-asserted-by":"publisher","first-page":"101997","DOI":"10.1016\/j.eclinm.2023.101997","article-title":"Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naive patients with spinal muscular atrophy and following switch from other therapies","volume":"59","author":"Pane","year":"2023","journal-title":"EClinicalMedicine."},{"key":"B23","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.1007\/s12325-023-02685-w","article-title":"Patient and caregiver outcomes after onasemnogene abeparvovec treatment: findings from the cure sma 2021 membership survey","volume":"40","author":"Toro","year":"2023","journal-title":"Adv Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.nmd.2023.11.010","article-title":"Continued safety and long-term effectiveness of onasemnogene abeparvovec in ohio","volume":"34","author":"Waldrop","year":"2023","journal-title":"Neuromuscul Disord."},{"key":"B25","doi-asserted-by":"publisher","first-page":"100817","DOI":"10.1016\/j.lanepe.2023.100817","article-title":"Efficacy and safety of onasemnogene abeparvovec in children with spinal muscular atrophy type 1: real-world evidence from 6 infusion centres in the United Kingdom","volume":"37","author":"Gowda","year":"2024","journal-title":"Lancet Reg Health Eur."},{"key":"B26","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12883-023-03133-6","article-title":"Treatment of spinal muscular atrophy with onasemnogene abeparvovec in Switzerland: a prospective observational case series study","volume":"23","author":"Stettner","year":"2023","journal-title":"BMC Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/mus.27926","article-title":"Gene transfer therapy in children with spinal muscular atrophy: a single-center experience with a cohort of 25 children","volume":"68","author":"Chencheri","year":"2023","journal-title":"Muscle Nerve."},{"key":"B28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.pediatrneurol.2023.04.007","article-title":"Real-life outcome after gene replacement therapy for spinal muscular atrophy: a multicenter experience","volume":"144","author":"Tokatly Latzer","year":"2023","journal-title":"Pediatr Neurol."},{"key":"B29","unstructured":"Spinraza (Nusinersen)."},{"key":"B30","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","article-title":"The children's hospital of philadelphia infant test of neuromuscular disorders (chop intend): test development and reliability","volume":"20","author":"Glanzman","year":"2010","journal-title":"Neuromuscul Disord."},{"key":"B31","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/PEP.0b013e3182351f04","article-title":"Validation of the children's hospital of philadelphia infant test of neuromuscular disorders (chop intend)","volume":"23","author":"Glanzman","year":"2011","journal-title":"Pediatr Phys Ther."},{"key":"B32","unstructured":"Best Practices for Physical Therapists & Clinical Evaluators in Spinal Muscular Atrophy (Sma). Recommendations to Support the Effective Conduct of Clinical Trials in Sma2021"},{"key":"B33","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2102047","article-title":"Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls","volume":"385","author":"Darras","year":"2021","journal-title":"N Engl J Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1212\/WNL.92.15_supplement.S25.001","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 nurture study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul Disord."},{"key":"B35","volume-title":"Griffiths Scales of Child Development (3rd Edition)","author":"Green","year":"2016"},{"key":"B36","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/ana.25533","article-title":"Nusinersen in type 1 spinal muscular atrophy: twelve-month real-world data","volume":"86","author":"Pane","year":"2019","journal-title":"Ann Neurol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/S1474-4422(22)00339-8","article-title":"Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (firefish part 2): secondary analyses from an open-label trial","volume":"21","author":"Masson","year":"2022","journal-title":"Lancet Neurol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/acn3.51276","article-title":"Type I SMA \u201cnew natural history\u201d: long-term data in nusinersen-treated patients","volume":"8","author":"Pane","year":"2021","journal-title":"Ann Clin Transl Neurol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e0202104","DOI":"10.1371\/journal.pone.0202104","article-title":"Spinal muscular atrophy within amish and mennonite populations: ancestral haplotypes and natural history","volume":"13","author":"Carson","year":"2018","journal-title":"PLoS ONE."},{"key":"B40","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.nmd.2016.10.002","article-title":"Developmental milestones in type i spinal muscular atrophy","volume":"26","author":"De Sanctis","year":"2016","journal-title":"Neuromuscul Disord."},{"key":"B41","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1212\/CPJ.0000000000001179","article-title":"Scoliosis in spinal muscular atrophy type 1 in the nusinersen era","volume":"12","author":"Al Amrani","year":"2022","journal-title":"Neurol Clin Pract."},{"key":"B42","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.arcped.2014.01.017","article-title":"Multicentric study of medical care and practices in spinal muscular atrophy type 1 over two 10-year periods","volume":"21","author":"Barn\u00e9rias","year":"2014","journal-title":"Arch Pediatr."},{"key":"B43","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type i and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology."},{"key":"B44","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S0960-8966(01)00274-7","article-title":"Intelligence and cognitive function in children and adolescents with spinal muscular atrophy","volume":"12","author":"von Gontard","year":"2002","journal-title":"Neuromuscul Disord."},{"key":"B45","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1590\/1980-57642018dn13-040011","article-title":"Cognitive performance of children with spinal muscular atrophy: a systematic review","volume":"13","author":"Polido","year":"2019","journal-title":"Dement Neuropsychol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s11689-021-09355-4","article-title":"Intellectual abilities, language comprehension, speech, and motor function in children with spinal muscular atrophy type 1","volume":"13","author":"Zappa","year":"2021","journal-title":"J Neurodev Disord."},{"key":"B47","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1080\/10400435.2019.1586788","article-title":"Communication skills among children with spinal muscular atrophy type 1: a parent survey","volume":"33","author":"Ball","year":"2021","journal-title":"Assist Technol."},{"key":"B48","first-page":"115","article-title":"Milestones for communication development in Japanese children with spinal muscular atrophy type 1","volume":"14","author":"Hoshi","year":"2017","journal-title":"J Health Sci."},{"key":"B49","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ppul.24203","article-title":"Health outcomes in spinal muscular atrophy type 1 following avxs-101 gene replacement therapy","volume":"54","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr Pulmonol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejpn.2023.02.004","article-title":"Neurocognitive profile of a cohort of sma type 1 pediatric patients and emotional aspects, resilience and coping strategies of their caregivers","volume":"43","author":"Tosi","year":"2023","journal-title":"Eur J Paediatr Neurol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/mus.27187","article-title":"Safety and efficacy of nusinersen in spinal muscular atrophy: the embrace study","volume":"63","author":"Acsadi","year":"2021","journal-title":"Muscle Nerve."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s40264-021-01107-6","article-title":"Clinical trial and postmarketing safety of onasemnogene abeparvovec therapy","volume":"44","author":"Day","year":"2021","journal-title":"Drug Saf."},{"key":"B53","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J Hepatol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3233\/JND-200593","article-title":"Safety monitoring of gene therapy for spinal muscular atrophy with onasemnogene abeparvovec -a single centre experience","volume":"8","author":"Friese","year":"2021","journal-title":"J Neuromuscul Dis."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1326528\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:50:51Z","timestamp":1708476651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1326528\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":54,"alternative-id":["10.3389\/fneur.2024.1326528"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1326528","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,21]]},"article-number":"1326528"}}